Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 2/20 | 0.36 |
| ▸ | BACE1 | P56817 | 10/20 | 0.34 |
| ▸ | BACE2 | Q9Y5Z0 | 4/20 | 0.34 |
| ▸ | UGCG | Q16739 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | CTSL | P07711 | 1/20 | 0.33 |
| ▸ | TACR1 | P25103 | 2/20 | 0.33 |
| ▸ | CTSD | P07339 | 6/20 | 0.32 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.32 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.32 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5751713 | 0.90 | BACE1 (0.34) | PTGER4BACE1BACE2UGCGCTSL | |
| SCHEMBL5752139 | 0.88 | BACE1 (0.39) | PTGER4BACE1BACE2UGCGCTSL | |
| SCHEMBL5751536 | 0.88 | PTGER4 (0.38) | PTGER4BACE1BACE2UGCGCTSD | |
| SCHEMBL1900082 | 0.87 | PTGER4 (0.38) | PTGER4BACE1BACE2UGCGTACR1 | |
| SCHEMBL5752551 | 0.87 | UGCG (0.33) | PTGER4BACE1BACE2UGCG | |
| SCHEMBL5754766 | 0.87 | BACE1 (0.34) | PTGER4BACE1BACE2UGCGCTSD | |
| SCHEMBL5751109 | 0.87 | UGCG (0.39) | PTGER4BACE1BACE2UGCGCTSD | |
| SCHEMBL5751900 | 0.86 | UGCG (0.33) | PTGER4BACE1BACE2UGCG | |
| SCHEMBL5752436 | 0.86 | BACE1 (0.38) | PTGER4BACE1BACE2UGCGTACR1 | |
| SCHEMBL5751530 | 0.85 | CETP (0.35) | BACE1BACE2UGCG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6982348-B2 | Aminoethanol derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-01-03 | — | — | US | disclosed |
| US-20040127574-A1 | Aminoethanol derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127574-A1 | Aminoethanol derivatives | CETP, LCAT, MTTP | PTGER4 1632/4885BACE1 835/4885BACE2 1392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.